» Articles » PMID: 19843073

LAPTM4B-35, a Novel Tetratransmembrane Protein and Its PPRP Motif Play Critical Roles in Proliferation and Metastatic Potential of Hepatocellular Carcinoma Cells

Overview
Journal Cancer Sci
Specialty Oncology
Date 2009 Oct 22
PMID 19843073
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Lysosomal protein transmembrane 4 beta (LAPTM4B) was originally identified as a hepatocellular carcinoma (HCC)-associated gene. This gene and its protein product LAPTM4B-35, are both overexpressed in a variety of human cancers. However, its specific role in cell transformation and malignancy has remained elusive. In the present study we investigated the effects of LAPTM4B-35 overexpression on the malignant phenotypic features in the HLE cell line. Our data show that overexpression of LAPTM4B-35 promotes cell proliferation, exogenous growth-stimulating factor-independent and anchorage-independent growth, and enhances metastatic potential, including promotion of both cell migration and invasion. Study of the underlying mechanisms demonstrated alterations of molecular events involved in these processes, which included upregulation of proliferation-promoting transcription factors such as c-Myc, c-Jun, and c-Fos, and cell cycle-promoting proteins such as cyclin D1 and cyclin E. In addition, mutagenesis study showed that the PPRP motif in the N-terminal region of LAPTM4B-35 plays a critical role in promoting proliferation, migration, and invasion, as well as in the upregulation of the oncoproteins noted above. These data offer insight into the mechanism by which this novel tetratransmembrane protein contributes to the pathogenesis of liver cancer, and suggest that it may be a potential target for cancer therapy.

Citing Articles

Genome-Wide Characterization of Somatic Mutation Patterns in Cloned Dogs Reveals Implications for Neuronal Function, Tumorigenesis, and Aging.

Woo S, Kim M, Kang D, Choe Y, Oh S, You A Genes (Basel). 2024; 15(6).

PMID: 38927737 PMC: 11202621. DOI: 10.3390/genes15060801.


LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.

Wang H, Zhou Q, Xie D, Xu Q, Yang T, Wang W Cell Death Dis. 2024; 15(2):165.

PMID: 38388484 PMC: 10884007. DOI: 10.1038/s41419-024-06542-8.


LAPTM4B-YAP loop feedback amplification enhances the stemness of hepatocellular carcinoma.

Liao J, Wang J, Xu Y, Wu Y, Wang M, Zhao Q iScience. 2023; 26(6):106754.

PMID: 37213231 PMC: 10197148. DOI: 10.1016/j.isci.2023.106754.


miR-137-LAPTM4B regulates cytoskeleton organization and cancer metastasis via the RhoA-LIMK-Cofilin pathway in osteosarcoma.

Yan R, Liu D, Wang J, Liu M, Guo H, Bai J Oncogenesis. 2023; 12(1):25.

PMID: 37147294 PMC: 10163001. DOI: 10.1038/s41389-023-00471-5.


Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer.

Gan X, Li S, Wang Y, Du H, Hu Y, Xing X Int J Mol Sci. 2023; 24(6).

PMID: 36982561 PMC: 10053938. DOI: 10.3390/ijms24065482.


References
1.
Kaneko T, Li L, Li S . The SH3 domain--a family of versatile peptide- and protein-recognition module. Front Biosci. 2008; 13:4938-52. DOI: 10.2741/3053. View

2.
Jochum W, Passegue E, Wagner E . AP-1 in mouse development and tumorigenesis. Oncogene. 2001; 20(19):2401-12. DOI: 10.1038/sj.onc.1204389. View

3.
Yang Y, Yang H, McNutt M, Xiong F, Nie X, Li L . LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep. 2008; 20(5):1077-83. View

4.
Yang T, Sinai P, Kain S . An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells. Anal Biochem. 1996; 241(1):103-8. DOI: 10.1006/abio.1996.0383. View

5.
Milde-Langosch K . The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 2005; 41(16):2449-61. DOI: 10.1016/j.ejca.2005.08.008. View